The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Rhea-AI Summary

Can-Fite BioPharma Ltd. (CANF) reports new data on Namodenoson's potential as an anti-obesity drug, highlighting its ability to reduce body weight and inhibit fat levels. The global obesity treatment market is projected to reach $100 billion by 2030, making Namodenoson a potential contender in this lucrative market.

Positive

• Namodenoson's new data showing a reduction in body weight and fat levels in experimental animal models
• Potential for Namodenoson to be developed as an anti-obesity drug based on preclinical data and excellent safety profile in humans
• Projected $100 billion market for anti-obesity medications by 2030 according to Goldman Sachs Research

Negative

• None.

Insights

Medical Research Analyst

The recent findings related to Can-Fite BioPharma's Namodenoson suggest a promising avenue in the treatment of obesity, a condition with significant global prevalence. The modulation of proteins to increase adiponectin levels indicates a targeted approach to managing fat production, which is a novel mechanism in the landscape of anti-obesity drugs. The observed weight loss in both preclinical and early clinical settings, combined with a favorable safety profile, underscores the potential of Namodenoson as a therapeutic candidate.

The economic implications are considerable, given the projected expansion of the anti-obesity market to $100 billion by 2030. This growth is propelled by rising obesity rates and the associated increase in comorbidities such as diabetes and cardiovascular diseases. Can-Fite BioPharma's progress could position them as a key player in this market, subject to the successful completion of clinical trials and regulatory approval processes.

Investors and stakeholders should monitor subsequent clinical trial results closely, as these will provide more definitive evidence of the drug's efficacy and safety, which are critical determinants of its commercial success. Moreover, the competitive landscape of the anti-obesity pharmaceutical market must be considered, as numerous companies are vying for market share with a variety of therapeutic approaches.

Financial Analyst

From a financial perspective, the development of Namodenoson represents a strategic investment in a high-growth sector. The obesity treatment market's projected growth to $100 billion by 2030 indicates a substantial opportunity for Can-Fite BioPharma. The company's stock valuation could be significantly influenced by the market's anticipation of Namodenoson's entry and potential market share capture.

Key financial metrics to watch include the burn rate of Can-Fite BioPharma's R&D expenditures, the scale of investment required for Phase III clinical trials and partnership or licensing deals that may offset costs and provide upfront revenue. The 2.1% weight loss observed in the Phase IIa NASH study, while seemingly modest, is clinically relevant and could translate into substantial market potential if such results are replicated in larger patient populations.

It is essential for investors to assess the risk associated with the drug's development trajectory, including regulatory hurdles and the possibility of delayed market entry. Market dynamics, reimbursement policies and competitive pricing will also play crucial roles in the financial outcome of Namodenoson's commercialization.

Industry Analyst

The anti-obesity medication sector is undergoing significant evolution, with a shift towards drugs that offer both weight reduction and favorable safety profiles. Namodenoson's mechanism of action, targeting adiponectin modulation, places it within a class of drugs that could potentially offer a differentiated value proposition. This is particularly relevant in an industry where the efficacy-to-safety ratio is a key driver of drug adoption.

Strategic alliances and market access strategies will be pivotal for Can-Fite BioPharma as they navigate the complex regulatory and competitive environment. The company's ability to secure favorable terms in distribution and marketing partnerships could enhance its market penetration and adoption rates upon commercial release.

Understanding the nuanced needs of the patient population and tailoring marketing approaches to emphasize the clinical benefits of Namodenoson will be essential. Additionally, the impact of new entrants and existing treatments on the market dynamics cannot be underestimated. Can-Fite BioPharma must remain vigilant to maintain a competitive edge as the market landscape continues to evolve.

Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported new data on Namodenoson’s anti-obesity mechanism of action.

New data demonstrate that treatment of fat cells (3T3-L1 adipocytes) with Namodenoson leads to modulation of proteins that increase adiponectin level. Adiponectin is a regulator of fat production in the cells, resulting in the inhibition of fat levels. Furthermore, Namodenoson reduced body weight in an experimental animal model of obesity induced by a high fat diet. In a Phase IIa NASH study, in patients treated with Namodenoson, a 2.1% weight loss was observed after 3 months of treatment (Safadi at Al) and a significant decrease in serum adiponectin levels was found.

“These new preclinical data, together with the excellent safety profile of Namodenoson in humans demonstrated to date, serve as robust support for its potential development as an anti-obesity drug,” said Pnina Fishman, Ph.D., CSO & Executive Chairman of Can-Fite BioPharma.

The global obesity treatment market is lucrative due to the awareness of a link between chronic diseases and obesity. The World Health Organization reports that obesity has nearly tripled since 1975 and at least 2.8 million people are dying as a results of obesity each year. According to Goldman Sachs Research, the anti-obesity medications market is estimated reached $6 billion on an annualized basis in 2023 and is expected to grow to $100 billion by 2030.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite's cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of steatotic liver disease (SLD), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.canfite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 30, 2023 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231220739293/en/

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114

Source: Can-Fite BioPharma Ltd.

FAQ

What new data did Can-Fite BioPharma Ltd. (CANF) report on Namodenoson?

Can-Fite BioPharma Ltd. reported new data on Namodenoson's anti-obesity mechanism of action, demonstrating its ability to reduce body weight and inhibit fat levels in experimental animal models.

What is the projected market size for anti-obesity medications by 2030?

According to Goldman Sachs Research, the anti-obesity medications market is estimated to reach $100 billion by 2030.

How does Namodenoson demonstrate potential as an anti-obesity drug?

Namodenoson's new data show a reduction in body weight and fat levels in experimental animal models, along with an excellent safety profile in humans, supporting its potential as an anti-obesity drug.

What is the potential impact of Namodenoson in the global obesity treatment market?

Namodenoson has the potential to be a contender in the global obesity treatment market, which is projected to reach $100 billion by 2030, based on its ability to reduce body weight and inhibit fat levels.